Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 156 Breast Neoplasms 142 Prostatic Neoplasms 127 Lung Neoplasms 124 Glioblastoma 112 Head and Neck Neoplasms 106 Rectal Neoplasms 97 Lymphoma 96 Squamous Cell Carcinoma of Head and Neck 94 Esophageal Neoplasms 91 Pancreatic Neoplasms 70 Leukemia 65 Esophageal Squamous Cell Carcinoma 64 Neoplasms 60 Brain Neoplasms 60 Precursor Cell Lymphoblastic Leukemia-Lymphoma 57 Lymphoma, Non-Hodgkin 57 Lymphoma, Follicular 57 Lymphoma, Large B-Cell, Diffuse 52 Hodgkin Disease 52 Central Nervous System Neoplasms 50 Leukemia, Lymphocytic, Chronic, B-Cell 48 Gliosarcoma 47 Uterine Cervical Neoplasms 45 Sarcoma 45 Colorectal Neoplasms 44 Lymphoma, Large-Cell, Immunoblastic 41 Glioma 41 Burkitt Lymphoma 41 Lymphoma, Mantle-Cell 39

Interventions

nimotuzumab 1 atezolizumab 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡